ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022 Final Analysis of the Randomized, Phase 3 RATIONALE-301 Study: Tislelizumab vs. Sorafenib as 1L Treatment for Unresectable HCC
By
ESMO 2022 Conference Coverage
FEATURING
Masatoshi Kudo
By
ESMO 2022 Conference Coverage
FEATURING
Masatoshi Kudo
104 views
September 19, 2022
Comments 0
Login to view comments.
Click here to Login
GI